New! Sign up for our free email newsletter.
Science News
from research organizations

Respiratory allergies: Newly discovered molecule plays a major role in triggering inflammation

Date:
April 10, 2024
Source:
CNRS
Summary:
One of the molecules responsible for triggering the inflammation that causes allergic respiratory diseases, such as asthma and allergic rhinitis, has just been discovered. This molecule, from the alarmin family, represents a therapeutic target of major interest for the treatment of allergic diseases.
Share:
FULL STORY

One of the molecules responsible for triggering the inflammation that causes allergic respiratory diseases, such as asthma and allergic rhinitis, has just been discovered by scientists from the CNRS, Inserm and the Université Toulouse III -- Paul Sabatier. This molecule, from the alarmin family, represents a therapeutic target of major interest for the treatment of allergic diseases. The study, co-directed by Corinne Cayrol and Jean-Philippe Girard, is published in the Journal of Experimental Medicine on 10 April.

The inflammation process plays a crucial role in allergic respiratory diseases, such as asthma and allergic rhinitis. Although the pulmonary epithelium, the carpet of cells that forms the inner surface of the lungs, is recognised as a major player in the respiratory inflammation that causes these diseases, the underlying mechanisms are still poorly understood.

A research team has identified one of the molecules responsible for triggering these allergic reactions, in a study co-led by two CNRS and Inserm scientists working at l'Institut de pharmacologie et de biologie structural (CNRS/Université Toulouse III -- Paul Sabatier). This molecule from the alarmin family, named TL1A, is released by lung epithelium cells a few minutes after exposure to a mould-type allergen. It cooperates with another alarmin, interleukin-33, to alert the immune system. This double alarm signal stimulates the activity of immune cells, triggering a cascade of reactions responsible for allergic inflammation.

Alarmins, therefore, constitute major therapeutic targets for the treatment of respiratory allergic diseases. In a few years' time, treatments based on antibodies blocking the TL1A alarmin could benefit patients suffering from severe asthma or other allergic diseases. In France, at least 17 million people are affected by allergic diseaseswith the most severe forms of asthma being responsible for several hundred deaths every year.


Story Source:

Materials provided by CNRS. Note: Content may be edited for style and length.


Journal Reference:

  1. Pauline Schmitt, Anais Duval, Mylène Camus, Emma Lefrançais, Stéphane Roga, Cécile Dedieu, Nathalie Ortega, Elisabeth Bellard, Emilie Mirey, Emmanuelle Mouton-Barbosa, Odile Burlet-Schiltz, Anne Gonzalez-de-Peredo, Corinne Cayrol, Jean-Philippe Girard. TL1A is an epithelial alarmin that cooperates with IL-33 for initiation of allergic airway inflammation. Journal of Experimental Medicine, 2024; 221 (6) DOI: 10.1084/jem.20231236

Cite This Page:

CNRS. "Respiratory allergies: Newly discovered molecule plays a major role in triggering inflammation." ScienceDaily. ScienceDaily, 10 April 2024. <www.sciencedaily.com/releases/2024/04/240410112629.htm>.
CNRS. (2024, April 10). Respiratory allergies: Newly discovered molecule plays a major role in triggering inflammation. ScienceDaily. Retrieved May 24, 2024 from www.sciencedaily.com/releases/2024/04/240410112629.htm
CNRS. "Respiratory allergies: Newly discovered molecule plays a major role in triggering inflammation." ScienceDaily. www.sciencedaily.com/releases/2024/04/240410112629.htm (accessed May 24, 2024).

Explore More

from ScienceDaily

RELATED STORIES